Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20250017 | 0.89 | ELOVL1 (0.77) | ELOVL1ALDH1A1KMT2ARAB9ALMNA | |
| SCHEMBL20249947 | 0.87 | ELOVL1 (0.64) | ELOVL1ALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL20250016 | 0.85 | ELOVL1 (0.86) | ELOVL1ALDH1A1KMT2ARAB9AMEN1 | |
| SCHEMBL20249741 | 0.84 | ELOVL1 (0.80) | ELOVL1MAPTCACNA1GCACNA1HCACNA1I | |
| SCHEMBL20485390 | 0.83 | ELOVL1 (0.78) | ELOVL1ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL20250176 | 0.83 | ELOVL1 (0.78) | ELOVL1ALDH1A1KMT2ARAB9AMEN1 | |
| SCHEMBL20242031 | 0.82 | ELOVL1 (1.00) | ELOVL1ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL20249761 | 0.81 | ELOVL1 (0.79) | ELOVL1ALDH1A1KMT2ALMNAMAPT | |
| SCHEMBL20250077 | 0.81 | ELOVL1 (0.68) | ELOVL1ALDH1A1KMT2ARAB9ALMNA | |
| SCHEMBL20249783 | 0.81 | ELOVL1 (0.82) | ELOVL1ALDH1A1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | claimed |
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| WO-2018107056-A1 | 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | ELOVL1 39/4885ALDH1A1 69/4885KMT2A 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.